Dicerna Pharmaceuticals
Delivering RNAi-based breakthrough therapies to improve lives.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $3.3b Valuation: $3.3b | Acquisition | |
| Total Funding | 000k | ||
Skyline Ventures(exited)
Abingworth(exited)
Kyowa Kirin(exited)
SR One(exited)
HealthCare Ventures(exited)
Oxford Bioscience Partners(exited)
RA Capital Management(exited)
Omega Funds(exited)
Domain Associates(exited)
Deerfield Partners(exited)
Brookside Capital(exited)
Bain Capital Ventures(exited)
EcoR1 Capital(exited)
Cormorant Asset Management(exited)
Hercules Capital(exited)
Bain Capital Life Sciences(exited)
Access Biotechnology(exited)
Eli Lilly(exited)
Aquilo Capital Management(exited)
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 500 % | 283 % | 613 % | 18 % | (1 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (5000 %) | (1000 %) | (552 %) | (68 %) | (74 %) | (112 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (6000 %) | (1467 %) | (522 %) | (69 %) | (66 %) | (78 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 2860 % | 587 % | 340 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.